"Texas Retina Associates is Texas’ largest, most experienced ophthalmology practice focused specifically on the diagnosis and management of diseases of the retina and vitreous, including macular degeneration and diabetic retinopathy. Training at some of the country’s top medical institutions, all of our physicians completed fellowships in retina care, and many have sub-specialized further to treat even the most challenging retina conditions like uveitis and ocular oncology."

During the past decade, Texas Retina Associates conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 19 clinical trials were completed, i.e. on average, 73.1% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 14 clinical trials were completed. i.e. 155.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Retina Associates" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Allergan" with 4 trials sponsored, "Clearside Biomedical, Inc." with 3 trials sponsored, "National Eye Institute (NEI)" with 3 trials sponsored and "EyePoint Pharmaceuticals, Inc." with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Retina Associates" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Allergan" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 2 trials as a collaborator and "Alcon Research" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Texas Retina Associates" are "Diabetic Macular Edema" (10 trials), "Macular Degeneration" (7 trials), "Geographic Atrophy" (5 trials), "Macular Edema" (4 trials) and "Neovascular Age-Related Macular Degeneration" (3 trials). Many other conditions were trialed in "Texas Retina Associates" in a lesser frequency.

Most popular intervention types in "Texas Retina Associates" are "Drug" (41 trials), "Other" (7 trials), "Biological" (4 trials), "Procedure" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Ranibizumab" (8 trials), "Sham Procedure" (4 trials), "Sham injection" (3 trials) and "ranibizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Retina Associates" are 45 trials for "All" genders.

Currently, there are NaN active trials in "Texas Retina Associates". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Texas Retina Associates, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Retina Associates, 4 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".